Recent Company News

• 07:03 AM ET Jun 11, 2026
  

  Purple Biotech announces presentation of new preclinical data from its lead CAPTN-3 program, IM1240, at the European Association for Cancer Research (EACR) 2026 Annual Congress (1.00a, 0.00)

• 05:31 PM ET May 20, 2026
  

  Purple Biotech files $200M mixed shelf; enters into sales agreement for up to $0.8M with H.C. Wainwright - F-3 (1.00a, 0.00)

• 07:05 AM ET May 15, 2026
  

  Purple Biotech reports Q1 net income ($0.1M) vs year-ago ($0.5M) (1.00a, 0.00)

• 07:06 AM ET Apr 27, 2026
  

  Purple Biotech announces new preclinical data supporting the clinical potential of IM1240 (1.00a, 0.00)

• 07:05 AM ET Apr 23, 2026
  

  Purple Biotech establishes scientific advisory board to support development of CAPTN-3 tri-specific antibody platform (1.00a, 0.00)

• 08:05 AM ET Mar 13, 2026
  

  Purple Biotech announces CEO Gil Efron to step down; initiates CEO search ($3.84, 0.00)

• 08:03 AM ET Mar 13, 2026
  

  Purple Biotech reports Q4 EPS $0.10 vs year-ago $0.00 ($3.84, 0.00)

• 04:51 PM ET Feb 25, 2026
  

  Purple Biotech announces plan to implement ADS ratio change having same effect as 1:10 reverse split, effective 2-Mar-26 ($0.52, 0.00)

• 08:05 AM ET Jan 07, 2026
  

  Purple Biotech provides update on toxicology study of CAPTN-3 tri-specific antibody IM1240 ($0.70, 0.00)

• 07:11 AM ET Dec 11, 2025
  

  Purple Biotech reports new preclinical data on two CAPTN-3 tri-specific antibodies at ESMO Immuno-Oncology Congress 2025 ($0.83, 0.00)